Clinical Trials
9 trialsNCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT00892736 2018-06-29
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT02210663 2018-05-07
A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT01145430 2017-12-22
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00526617 2017-11-21
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
AbbVie
Phase 1 Completed
NCT02009631 2017-11-20
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
AbbVie
Phase 1 Completed
NCT03032614 2017-10-10
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT01306032 2017-04-26
Phase II ABT-888 With Cyclophosphamide
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02033551 2016-09-27
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
AbbVie
Phase 1 Completed